{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:21:47Z","timestamp":1762100507667},"reference-count":32,"publisher":"Elsevier BV","issue":"44-46","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.vaccine.2006.05.080","type":"journal-article","created":{"date-parts":[[2006,6,11]],"date-time":"2006-06-11T09:58:40Z","timestamp":1150019920000},"page":"6660-6663","source":"Crossref","is-referenced-by-count":14,"title":["Active metabolite from Tamiflu\u00ae solution is bioequivalent to that from capsule delivery in healthy volunteers: A cross-over, randomised, open-label study"],"prefix":"10.1016","volume":"24","author":[{"given":"M.","family":"Brewster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dutkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Robson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.05.080_bib1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/oxfordjournals.aje.a113052","article-title":"Impact of epidemic type A influenza in a defined adult population","volume":"112","author":"Barker","year":"1980","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2006.05.080_bib2","series-title":"The influenza virus and influenza","author":"Kilbourne","year":"1975"},{"issue":"RR\u20138","key":"10.1016\/j.vaccine.2006.05.080_bib3","first-page":"1","article-title":"Prevention and control of influenza. Recommendations of the advisory committee on immunization practices (ACIP)","volume":"52","author":"Bridges","year":"2003","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2006.05.080_bib4","first-page":"S247","article-title":"Advances in the prophylaxis and treatment of influenza illness","volume":"6","author":"Hayden","year":"2000","journal-title":"Am J Manage Care"},{"key":"10.1016\/j.vaccine.2006.05.080_bib5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1128\/AAC.42.3.640","article-title":"Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection","volume":"42","author":"Mendel","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2006.05.080_bib6","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","article-title":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial","volume":"355","author":"Nicholson","year":"2000","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2006.05.080_bib7","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza A randomized controlled trial","volume":"283","author":"Treanor","year":"2000","journal-title":"J Am Med Assoc"},{"issue":"14","key":"10.1016\/j.vaccine.2006.05.080_bib8","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/archinte.163.14.1667","article-title":"Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations","volume":"163","author":"Kaiser","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.vaccine.2006.05.080_bib9","unstructured":"Nordstrom B, Zhu S, Smith J. Reduced risk of mortality following oseltamivir use: a retrospective cohort study. J Antimicrob Chemother submitted for publication."},{"issue":"5","key":"10.1016\/j.vaccine.2006.05.080_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1185\/030079905X46214","article-title":"Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir","volume":"21","author":"Nordstrom","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.vaccine.2006.05.080_bib11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1086\/381128","article-title":"Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis","volume":"189","author":"Hayden","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.05.080_bib12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.285.6.748","article-title":"Effectiveness of oseltamivir in preventing influenza in household contacts","volume":"285","author":"Welliver","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2006.05.080_bib13","series-title":"Avian influenza: assessing the pandemic threat","author":"WHO","year":"2006"},{"issue":"7514","key":"10.1016\/j.vaccine.2006.05.080_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/bmj.331.7514.413","article-title":"H5N1 influenza and the implications for Europe","volume":"331","author":"Coulombier","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2006.05.080_bib15","unstructured":"WHO. Avian influenza \u2013 new areas with infection in birds \u2013 update 34, 13 October, 2005."},{"issue":"8","key":"10.1016\/j.vaccine.2006.05.080_bib16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1473-3099(04)01105-3","article-title":"Confronting the avian influenza threat: vaccine development for a potential pandemic","volume":"4","author":"Stephenson","year":"2004","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2006.05.080_bib17","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.45.10.2723-2732.2001","article-title":"Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses","volume":"45","author":"Govorkova","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.vaccine.2006.05.080_bib18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1086\/432008","article-title":"Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic a\/vietnam\/1203\/04 influenza virus in mice","volume":"192","author":"Yen","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.05.080_bib19","unstructured":"Roberts NA, Wiltshire HR, Mendel DB, Webster RG. Oseltamivir carboxylate is effective against all subtypes of influenza neuraminidase. In: ASM Biodefense Research Meeting; 2003; Baltimore, MD, USA, 2003."},{"key":"10.1016\/j.vaccine.2006.05.080_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(00)00123-6","article-title":"The neuraminidase inhibitor GS4014 (oseltamivir phosphate) is efficacious against A\/Hong Kong\/156\/97 (H5N1) and A\/Hong Kong\/1074\/99 (H9N2) influenza viruses","volume":"48","author":"Leneva","year":"2000","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2006.05.080_bib21","unstructured":"WHO. WHO guidelines on the use of vaccines and antivirals during influenza pandemics. WHO Gloval influenza programme (2004)."},{"key":"10.1016\/j.vaccine.2006.05.080_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0378-4347(00)00300-5","article-title":"Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine","volume":"745","author":"Wiltshire","year":"2000","journal-title":"J Chromatogr B"},{"issue":"6","key":"10.1016\/j.vaccine.2006.05.080_bib23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-199937060-00003","article-title":"Clinical pharmacokinetics of the prodrug oseltamivir and it active metabolite Ro 64-0802","volume":"37","author":"He","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.vaccine.2006.05.080_bib24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/00912700022009567","article-title":"The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir [Ro 64-0796\/GS4104] in healthy adult and elderly volunteers","volume":"40","author":"Massarella","year":"2000","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.05.080_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jac\/dkg007","article-title":"Early administration of oral oseltamivir increases the benefits of influenza treatment","volume":"51","author":"Aoki","year":"2003","journal-title":"J Antimicrobial Chemother"},{"issue":"11 Suppl","key":"10.1016\/j.vaccine.2006.05.080_bib26","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1097\/01.inf.0000144680.39895.ce","article-title":"Pandemic influenza: is an antiviral response realistic?","volume":"23","author":"Hayden","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2006.05.080_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.322.7286.577","article-title":"Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial","volume":"322","author":"Diggory","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2006.05.080_bib28","unstructured":"Roche FH-L. Tamiflu oseltamivir phosphate: product information; 2004."},{"key":"10.1016\/j.vaccine.2006.05.080_bib29","unstructured":"GlaxoSmithKline. Zanamivir: prescribing information; 2003."},{"issue":"7","key":"10.1016\/j.vaccine.2006.05.080_bib30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa044307","article-title":"Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma","volume":"352","author":"de Jong","year":"2005","journal-title":"N Engl J Med"},{"issue":"9409","key":"10.1016\/j.vaccine.2006.05.080_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(04)15589-X","article-title":"Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in The Netherlands","volume":"363","author":"Koopmans","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2006.05.080_bib32","first-page":"189","article-title":"Human infection by avian influenza A H5N1","volume":"11","author":"Yuen","year":"2005","journal-title":"Hong Kong Med J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06006396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06006396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T05:05:59Z","timestamp":1555650359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06006396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":32,"journal-issue":{"issue":"44-46","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0264410X06006396"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.05.080","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}